It’s time to start thinking about seasonal vaccinations. Getting those annual jabs isn’t quite as simple as it was before the ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but ...

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...

Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the ...

Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but ...

The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for ...

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.